Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Brief Report

High rate of Multidrug-Resistant Organisms (MDROs) among COVID-19 patients presenting with bacteremia upon hospital admission

Ashish Bhargava MD, FACP, FIDSA*, Kathleen Riederer MT (ASCP), Mamta Sharma MD, FACP, FIDSA, Elisa Akagi Fukushima MD, Leonard Johnson MD, FACP, FIDSA, Louis Saravolatz MD, MACP, FIDSA

Ascension St. John Hospital, Detroit, MI

We investigated the clinical implications of bacteremia among hospitalized COVID-19 patients. Higher rates (52.1%) of multidrug resistant organisms (MDRO) were noted on hospital admission compared to nosocomial acquisition (25%). Methicillin resistant Staphylococcus aureus was the predominant pathogen. Bacteremia with MDRO should be considered in the differential diagnosis among at risk populations especially those admitted from nursing facilities.

© 2021 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Key Words:
SARS-CoV-2
Bacteremia
Antimicrobial resistance
Bloodstream infections

Since its first detection in 2019, the novel pathogen, severe acute respiratory syndrome coronavirus (SARS-CoV-2) has spread to a pandemic level causing COVID-19. Without a clear treatment strategy in the early months of the pandemic, antibiotics were often used for possible bacterial coinfections.1-2 Blood culture (BC) was also performed to assess the presence of bacteremia that could complicate the clinical course.3 We investigated COVID-19 patients with bacteremia to ascertain the clinical implications for patients presenting with dual pathogens.

METHODS

A retrospective review was performed of the electronic medical records of adult patients admitted to a 776-bed tertiary care center in Detroit, Michigan. COVID-19 cases diagnosed by qualitative reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay between March and June 2020 were included. Data collection consisted of patient demographics, clinical information, and microbiologic results. The study was approved by the Ascension St. John Hospital Institutional Review Board.

We defined patients with bloodstream infection (BSI) on admission as a known pathogen in 1 or more BCs or the same commensal organism in 2 or more BCs drawn within 48 hours from time of admission. A nosocomial BSI was diagnosed if 1 or more cultures of blood drawn at least 48 hours after admission yielded a pathogenic organism. BCs were considered contaminated if there was a potential skin contaminant (eg, Diphtheroids, Bacillus species, or Coagulase-negative Staphylococci) in only 1 out of 2 BCs without clinical evidence of a true bacteremia as deemed by the treating infectious disease physician. BSI episodes that represented contamination and relapses were excluded. Multidrug-resistant organisms (MDROs) were defined as resistant to one or more classes of antimicrobial agents including methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant Enterococci (VRE) and certain gram negatives producing extended spectrum beta-lactamases (ESBLs) or Carbapenemase resistant Enterobacteriaceae (CRE)4

RESULTS

We identified 290 hospitalized patients with BC during the study period after exclusion of relapse and BC contaminants. There were 23 of 266 (8.6%) patients with positive BC on admission, all drawn within 26 hours of admission, and the majority were drawn in the emergency unit (Table 1). Nosocomial bacteremia was noted in 16 patients, 14 (87.5%) of them had BC done when they were in Intensive Care Units (ICU).
In our study, the rate of positive BC on admission among the hospitalized COVID-19 patients was 8.6% which is higher than 2.5%–2.9% reported in early literature. This is likely due to the higher number of patients (65%) with positive BC on admission from nursing facilities. We previously reported that admission from nursing facilities was an independent risk factor for bacteremia on admission. Similar findings of higher community-onset bacterial infection were reported among the patients admitted from a skilled nursing facility.

In our study, in-hospital mortality among patients with dual infection was 64.1%, compared to 53.1% reported in a multicenter study. In our cohort, gram positive MDRO BSIs were more common either on admission or nosocomially acquired. High rates of resistant BSIs on admission could be explained by those presenting from nursing facilities. A previous study on community onset BSI among non-COVID-19 patients reported that admission from a nursing facility was an independent risk factor for MDRO infections. Indwelling devices, such as urinary catheters and feeding tubes, are frequently used in nursing facilities. Compared with residents from nursing facilities without indwelling devices, residents with indwelling devices have a higher prevalence of MDRO colonization.

Our study limitations are a single center study with a small sample size. Nevertheless, our study strength is inclusion of nursing home patients with severe COVID-19 that had BSIs on admission. Larger studies may further validate our findings.

CONCLUSION

Higher rates of MDRO BSIs were noted among the hospitalized COVID-19 patients on hospital admission. Gram positive MDRO bloodstream infections were more common either on admission or nosocomially acquired with MRSA being the most common pathogen. Based on our findings in patients presenting from the nursing home with sepsis, MDRO BSI should be considered in the differential diagnosis and efforts should be made to avoid delaying the administration of appropriate antibiotic therapy.

ACKNOWLEDGMENTS

We thank Ms. Debra Cicchini for helping us to access the journal articles through the electronic library.

REFERENCES

1. Vaughn VM, Gandhi T, Petty LA, et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis. 2021;72:e533–e541. PMID:32820807; PMCID: PMC7409526.
2. Rothe K, Fehl S, Schneider J, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2021;40:859–869. PMID:3316176; PMCID: PMC7605734.
3. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol. 2020;58:e00875-20. PMID:32404882; PMCID: PMC7383550.
4. Centers for Disease Control and Prevention. Multidrug-resistant organisms (MDRO) management. Available at: https://www.cdc.gov/infectioncontrol/guidelines/mdro/. Accessed March 17, 2021.
5. Akagi E, Sharma M, Johnson LB, et al. Clinical features and risk factors for community-onset bloodstream infections among COVID-19 patients. Infect Control Hosp Epidemiol. 2021;42:899–901. PMID:33706821.
6. Bhatt PJ, Shau S, Brunetti L, et al. Risk factors and outcomes of hospitalized patients with severe COVID-19 and secondary bloodstream infections: a multicenter, Case-Control Study. Clin Infect Dis. 2020;72:e95–e1003. PMID:33261875; PMCID: PMC7711783.
7. Lim CJ, Cheng AC, Kong DC, Peleg AY. Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study. BMC Infect Dis. 2014;14:126. PMID:24552979; PMCID: PMC3975842.
8. Mody L, Krein SL, Saint S, et al. A targeted infection prevention intervention in nursing home residents with indwelling devices: a randomized clinical trial. JAMA Intern Med. 2015;175:714–723. Erratum in: JAMA Intern Med. 2015;175(7):1247. PMID:25775048; PMCID: PMC4420659.